Market Newsdesk

NEW YORK, Jan. 08, 2025 (GLOBE NEWSWIRE) — Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced that management will present at the 43^rd Annual J.P. Morgan Healthcare Conference on Thursday, January 16, 2025, at 7:30 am PT in San Francisco.

A live webcast of the presentation can be accessed by visiting the Events and Presentations section of the Company’s website: https://ir.protaratx.com. The webcast will be archived for a limited time following the presentation.

About Protara Therapeutics, Inc.

Protara is a clinical-stage biotechnology company committed to advancing transformative therapies for people with cancer and rare diseases. Protara’s portfolio includes its lead candidate, TARA-002, an investigational cell-based therapy in development for the treatment of non-muscle invasive bladder cancer (NMIBC) and lymphatic malformations (LMs). The Company is evaluating TARA-002 in an ongoing Phase 2 trial in NMIBC patients with carcinoma in situ (CIS) who are unresponsive or naïve to treatment with Bacillus Calmette-Guérin (BCG), as well as a Phase 2 trial in pediatric patients with LMs. Additionally, Protara is developing IV Choline Chloride, an investigational phospholipid substrate replacement for patients on parenteral nutrition who are otherwise unable to meet their choline needs via oral or enteral routes. For more information, visit www.protaratx.com.

Company Contact:

Justine O’Malley
Protara Therapeutics
[email protected]
646-817-2836

SALT LAKE CITY, Jan. 08, 2025 (GLOBE NEWSWIRE) — Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced members of its management team will present at the 43^rd Annual J.P. Morgan Healthcare Conference in San Francisco on Wednesday, Jan. 15, at 3:45pm PT (6:45pm ET).

The presentation will be available through a live webcast in the investor relations section of Myriad’s website at investor.myriad.com. An archived edition of the presentation will be available later that day.

About Myriad Genetics

Myriad Genetics is a leading genetic testing and precision medicine company dedicated to advancing health and well-being for all. Myriad develops and offers genetic tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where genetic insights can significantly improve patient care and lower healthcare costs. For more information, visit www.myriad.com.

Investor Contact

Matt Scalo
(801) 584-3532
[email protected]

Media Contact

Glenn Farrell
(385) 318-3718
[email protected]

authID’s deterministic biometric authentication products recognized for providing the highest level of proficiency in the Identity Proofing and Verification category

DENVER, COLORADO, Jan. 08, 2025 (GLOBE NEWSWIRE) — authID® (Nasdaq: AUID), a leading provider of biometric identity verification and authentication solutions, today announced its recognition by The Prism Project in its 2024 Biometric Digital Identity Prism Flagship Report as an Identity Proofing and Verification Luminary and a driving force within the industry.

Published by Acuity Market Intelligence, the leading biometric digital identity research consultancy, the report highlights the critical role of biometrics in reducing fraud, improving operational efficiency, preserving privacy, and enhancing user experience in the era of digital transformation.

“We are extremely pleased to see authID receive the top rank in this year’s Biometric Identity Flagship Report, which includes evaluations of more than 130 vendors and organizations operating in the global digital identity ecosystem,” said Rhon Daguro, CEO of authID. “This report is the industry’s most comprehensive proprietary market analysis and receiving the highest level of proficiency within the Prism Project landscape framework is a testament to our team’s commitment to excellence in biometric authentication and identity verification.”

In addition to explaining the rapidly evolving biometric digital identity landscape, this flagship report highlights the global potential that biometric digital identity solutions offer enterprises of all industries.

“It’s clear that biometrics will play a major role in reducing fraud and enhancing user experience in the upcoming era of digital transformation,” said Maxine Most, founder of The Prism Project and Acuity Market Intelligence. “Our latest report serves as a roadmap for the biometric digital identity ecosystem and a valuable resource for decision-makers seeking to understand, evaluate, and implement biometric digital identity technology and solutions like those offered by authID that not only prevent fraud but improve operational efficiency and protect end-user privacy.”

The Prism Project in particular highlights authID’s capabilities across several key differentiators, including:

• Growth & Resources: With a team of proven identity-industry veterans, authID is in a marked growth period and is quickly proving its capabilities as the go-to partner for customers interested in seamlessly integrating its Proof and Verified products into their daily user infrastructure.
• Proof Points: The Prism Project highlights authID’s support of customers including the American Board of Radiologists, ABM, and Beem, representing a wide range of identity use cases that deliver data privacy, compliance, and ease of use. “When digitization gets complicated, authID proves that truly secure identity can feel simple,” the report noted.
• Unique Positioning: With one-in-one-billion false-match accuracy, 700ms-verification speeds, and complete privacy protection, authID provides a holistic and adaptive platform that users can trust.
• Proprietary Versus Integrated Biometrics and Document Authentication: The Prism Project highlights authID’s organic compliance protocols, which safeguard user biometrics and privacy: “From a customer perspective, they don’t have to lift a finger—compliance is just a natural part of using authID’s cutting edge facial biometrics technology.”

“With the global biometric digital identity industry estimated by the Prism Project to generate over $315 billion in aggregate revenue and biometric transactions expected to total 5.6 trillion from 2024 through 2028, we are extremely pleased to see authID ranked as one of the industry leaders who will usher in a new era in the adoption of secure, frictionless authentication solutions,” said Erick Soto, Chief Product Officer of authID. “As the industry continues to mature, our leadership position in deterministic solutions will help ensure that our Proof and Verified identification platform continues to set the standard in allowing enterprises to know who’s behind the device for every digital interaction.”

About authID

authID® (Nasdaq: AUID) ensures enterprises “Know Who’s Behind the Device™” for every customer or employee login and transaction through its easy-to-integrate, patented, biometric identity platform. authID quickly and accurately verifies a user’s identity and eliminates any assumption of “who” is behind a device to prevent cybercriminals from compromising account openings or taking over accounts. Combining secure digital onboarding and biometric authentication and account recovery, with a fast, accurate, user-friendly experience, authID delivers biometric identity processing in 700ms. Binding a biometric root of trust for each user to their account, authID stops fraud at onboarding, detects and stops deepfakes, eliminates password risks and costs, and provides the fastest, frictionless, and the more accurate user identity experience demanded by today’s digital ecosystem. Contact us to discover how authID can help your organization secure your workforce or consumer applications against identity fraud, cyberattacks and account takeover.

About The Prism Project

The Prism Project (www.the-prism-project.com) is at the forefront of biometric and digital identity research and education. Created by Acuity Market Intelligence, it bridges the gap between identity technology experts and organizations seeking innovative solutions for digital transformation. Through industry collaboration and comprehensive research, The Prism Project empowers influencers and decision-makers to forge a secure, human-centric digital identity future.

About Acuity Market Intelligence

Acuity Market Intelligence (www.acuitymi.com) is a trusted research and strategic advisory firm specializing in biometrics, identity, and digital transformation. Known for delivering actionable insights and proprietary market forecasts, Acuity helps organizations navigate the rapidly evolving digital identity landscape with confidence and clarity.

For further information, interviews, sponsor inquiries, or to download Prism reports, please visit www.the-prism-project.com or contact [email protected].

Media Contacts

NextTech Communications

Walter Fowler
1-631-334-3864
[email protected]

Investor Relations Contacts

Gateway Group, Inc.

Cody Slach and Alex Thompson
1-949-574-3860
[email protected]
[email protected]

HOLLYWOOD, Fla., Jan. 08, 2025 (GLOBE NEWSWIRE) — NV5, a provider of technology, certification, and consulting solutions, announced today that the company entered 2025 with a budget exceeding $1 billion in gross revenues and has also announced a new goal to reach $1.6 billion in annual revenues by 2028.

Dickerson Wright, PE, Executive Chairman of NV5, said, “NV5 has a proven track record of achieving ambitious growth targets throughout our history. We have achieved this impressive growth while exceeding industry averages for profitability and remaining at the forefront of tech-enabled engineering solutions. Driven by our new leadership and industry tail winds, we look to capitalize on technology services and high-margin offerings to achieve accelerated organic growth and profitability. Today we are announcing a new goal of $1.6 billion in annual revenues by year 2028.”

“As we enter this new phase for NV5, our growth will continue to be driven by entrepreneurial professionals striving to deliver unique value to our clients through technical excellence, cross-selling initiatives, and technological innovations. Our $1.6 billion revenue target by 2028 will be driven by organic growth of our existing capabilities, as well as investments in strategic acquisitions in tech-based solutions and high-growth sectors,” said Ben Heraud, CEO of NV5.

About NV5

NV5 Global, Inc. (NASDAQ: NVEE) is a provider of technology, certification, and consulting solutions for public and private sector clients supporting utility, infrastructure, and building assets and systems. The Company primarily focuses on six business verticals: Utility services, infrastructure engineering, conformity assessment, buildings & technology, environmental health sciences, and geospatial services. NV5 operates out of more than 100 offices nationwide and abroad. For additional information, please visit the Company’s website at www.NV5.com. Also visit the Company on Twitter, LinkedIn, Facebook, and Vimeo.

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. The Company cautions that these statements are qualified by important factors that could cause actual results to differ materially from those reflected by the forward-looking statements contained in this news release. Such factors include: (a) changes in demand from the local and state government and private clients that we serve; (b) general economic conditions, nationally and globally, and their effect on the market for our services; (c) competitive pressures and trends in our industry and our ability to successfully compete with our competitors; (d) changes in laws, regulations, or policies; and (e) the “Risk Factors” set forth in the Company’s most recent SEC filings. All forward-looking statements are based on information available to the Company on the date hereof, and the Company assumes no obligation to update such statements, except as required by law.

Investor Relations Contact

NV5 Global, Inc.
Jack Cochran
Vice President, Marketing & Investor Relations
Tel: +1-954-637-8048
Email: [email protected]

Source: NV5 Global, Inc.

HINGHAM, Mass., Jan. 08, 2025 (GLOBE NEWSWIRE) — Microbot Medical Inc. (Nasdaq: MBOT) today announced that it has entered into definitive agreements for the purchase and sale of 3,788,550 shares of the Company’s common stock at a purchase price of $2.27 per share of common stock in a registered direct offering priced at-the-market under Nasdaq rules. In addition, in a concurrent private placement, the Company will issue unregistered short-term series H preferred investment options. The short-term series H preferred investment options to purchase up to 7,577,100 shares of common stock have an exercise price of $2.10 per share and are immediately exercisable following issuance for a period of two years thereafter. The closing of the registered direct offering and the concurrent private placement is expected to occur on or about January 9, 2025, subject to the satisfaction of customary closing conditions.

H.C. Wainwright & Co. is acting as the exclusive placement agent for the offerings.

The gross proceeds to the Company from the offerings are expected to be approximately $8.6 million, before deducting the placement agent’s fees and other offering expenses payable by the Company. The Company intends to use the net proceeds from the offerings for the continued development, commercialization and regulatory activities for the Company’s LIBERTY^® Robotic System, expansion and development of additional applications derived from the Company’s existing IP portfolio, and for working capital and other general corporate purposes.

The shares of common stock described above (but not the short-term series H preferred investment options issued in the concurrent private placement or the shares of common stock underlying such short-term series H preferred investment options) are being offered by the Company pursuant to a “shelf” registration statement on Form S-3 (File No. 333-275634) previously filed with the Securities and Exchange Commission (the “SEC”) and declared effective by the SEC on December 4, 2023. The offering of the shares of common stock is made only by means of a prospectus, including a prospectus supplement, forming a part of the effective registration statement. A final prospectus supplement and accompanying prospectus relating to the registered direct offering will be filed with the SEC. Electronic copies of the final prospectus supplement and accompanying prospectus may be obtained, when available, on the SEC’s website at http://www.sec.gov or by contacting H.C. Wainwright & Co., LLC at 430 Park Avenue, 3rd Floor, New York, NY 10022, by phone at (212) 856-5711 or e-mail at [email protected].

The short-term series H preferred investment options described above are being issued in a concurrent private placement under Section 4(a)(2) of the Securities Act of 1933, as amended (the “Securities Act”), and Regulation D promulgated thereunder and, along with the shares of common stock underlying the short-term series H preferred investment options, have not been registered under the Securities Act, or applicable state securities laws. Accordingly, the short-term series H preferred investment options and underlying shares of common stock may not be offered or sold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Securities Act and such applicable state securities laws.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

About Microbot Medical

Microbot Medical Inc. (NASDAQ: MBOT) is a pre-commercial stage medical technology company with a vision to improve the quality of care for millions of patients and providers globally. The Company has developed the world’s first single-use, fully disposable endovascular robotic system, which aims to eliminate traditional barriers to accessing advanced robotic systems.

Further information about Microbot Medical is available at http://www.microbotmedical.com.

Safe Harbor

Statements to future financial and/or operating results, future growth in research, technology, clinical development, commercialization and potential opportunities for Microbot Medical Inc. and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management, constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and the Federal securities laws. Any statements that are not historical fact (including, but not limited to statements that contain words such as “will,” “believes,” “plans,” “anticipates,” “expects” and “estimates”) should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, the completion of the offerings, the satisfaction of customary closing conditions related to the offerings, the intended use of proceeds from the offerings, the Company’s need for and ability to obtain additional working capital to continue its transition to a commercially focused company, market conditions, risks inherent in the development and/or commercialization of the LIBERTY^® Endovascular Robotic Surgical System, uncertainty in the results of regulatory pathways and regulatory approvals, including whether the FDA will grant 510(k) clearance to commercially market the LIBERTY^® Endovascular Robotic Surgical System in the United States, disruptions resulting from new and ongoing hostilities between Israel and the Palestinians and other neighboring countries, need and ability to obtain future capital, and maintenance of intellectual property rights. Additional information on risks facing Microbot Medical can be found under the heading “Risk Factors” in Microbot Medical’s periodic reports filed with the Securities and Exchange Commission (SEC), which are available on the SEC’s web site at www.sec.gov. Microbot Medical disclaims any intent or obligation to update these forward-looking statements, except as required by law.

Investor Contact:

[email protected]

– Production of approximately 35 EH/s of SEALMINER A2s through Q3 2025 remains on track.
– ~7 EH/s of SEALMINER A2s allocated for external sale have been ordered by customers, including the full receipt of related down payments.
– SEAL03 sample wafers with an anticipated chip efficiency of 10 J/TH expected in Q1 2025.
– SEAL04 R&D remains on track to achieve industry leading efficiency of 5 J/TH with anticipated initial tape-out in Q3 2025.

SINGAPORE, Jan. 08, 2025 (GLOBE NEWSWIRE) — Bitdeer Technologies Group (NASDAQ: BTDR) (“Bitdeer” or the “Company”), a world-leading technology company for blockchain and high-performance computing, today announced its unaudited mining and operations updates for December 2024.

Operational Update

• Self-mined Bitcoin: 145 Bitcoins.
• Mining Rig Manufacturing and R&D:
  • SEALMINER A1: Mass production of approximately 3.7 EH/s of mining rigs remains on track with 0.3 EH/s powered on, 0.3 EH/s delivered for installation, 0.6 EH/s in-transit to data centers and 2.5 EH/s in production.
  • SEALMINER A2:
    • Production of approximately 35 EH/s of mining rigs through Q3 2025 remains on track. First trial batch of Air cooling rigs are expected to be delivered to our mining datacenters for testing in January 2025.
    • ~29,000 units (~7 EH/s out of the 35 EH/s) of SEALMINER A2s allocated for external sale (both Air cooling and Hydro cooling), have been ordered by customers, including the full receipt of related down payments from customers. These mining rigs are expected to begin shipment in March through Q2 2025.
  • SEALMINER A3:
    • SEAL03 initial tape-out sample wafers with an expected chip efficiency of 10 J/TH are expected in Q1 2025.
  • SEALMINER A4:
    • SEAL04 R&D remains on track to achieve industry leading efficiency of 5 J/TH with anticipated initial tape-out in Q3 2025.
• HPC/AI:
  • Discussions are ongoing with multiple development partners and potential end users for selected sites.
  • Bitdeer AI cloud services powered by NVIDIA DGX SuperPod with H100 systems maintained an average utilization rate of approximately 90% for the month.
  • Co-hosted VLM Bootcamp with NVIDIA for participants to explore and create with VLM via Bitdeer AI Studio.
• Hosting:
  • Client-hosted machines decreased by 2,000 units while overall hashrate increased by 0.8 EH/s due to higher efficiency machines hosted by clients.
• Infrastructure:
  • Tydal, Norway, 40 MW phase 1 expansion has completed installation of transformers, with delivery and installation of electrical equipment currently in progress. The energization is currently pending for regulatory approval.
  • Rockdale, Texas, USA, 100 MW hydro-cooling conversion is on track for phased completion during Q1 2025.
  • Jigmeling, Bhutan, 500 MW construction is on track with the primary substation expected to be completed by Q1 2025.
  • Massillon, Ohio, USA, 221 MW substation construction started and is expected to be completed in Q3 2025. Building design is completed and construction is underway, expected to be completed in phases between Q3 and Q4 2025.
  • 1.1 GW of new power capacity is on track to come online in 2025.
• Financing:
  • Full repayment of the outstanding principal balance of US$10 million of the senior secured notes issued to sellers in the previously announced acquisition of TROLL HOUSING AS and TYDAL DATA CENTER AS.

Management Commentary

“2025 is poised to be a transformative year for Bitdeer, marked by many exciting milestones,” stated Linghui Kong, Chief Business Officer of Bitdeer. “With the mass production of our SEALMINER A1 and A2 well underway, we are set to significantly expand our self-mining hashrate and commence miner sales to third party customers. Looking ahead, the planned releases of SEALMINER A3 and A4 in 2025 further strengthen our position to become an industry leading supplier in the multi-billion dollar ASICs market. Further, we are on track to energize over 1.1 GW of our 2.5 GW power portfolio over the next twelve months. Sustaining this momentum across multiple initiatives is a testament to our team’s dedication and belief in our mission. As we move into 2025, we are eager to solidify Bitdeer’s position as a leader in the crypto industry as well as the broader technology sector.”

Production and Operations Summary

Metrics	Dec 2024	Nov 2024	Dec 2023
Total hash rate under management 1 (EH/s)	21.6	20.7	21.0
– Proprietary hash rate	8.9	8.8	8.4
• Self-mining	8.5	8.2	6.7
• Cloud Hash Rate	0.0	0.2	1.7
• Delivered but not hashing	0.4	0.4	–
– Hosting	12.7	11.9	12.6
Mining machines under management	175,000	178,000	215,000
– Self-owned2	85,000	86,000	86,000
– Hosted	90,000	92,000	129,000
Bitcoins mined (self-mining only)	145	150	434
Bitcoins held3	594	443	43

¹
Total hash rate under management as of December 31, 2024 across the Company’s three primary business lines: Self-mining, Cloud Hash Rate, and Hosting.

• Self-mining refers to cryptocurrency mining for the Company’s own account, which allows it to directly capture the high appreciation potential of cryptocurrency.
• Cloud Hash Rate offers hash rate subscription plans and shares mining income with customers under certain arrangements. The Cloud Hash Rate stated above reflects the contracted hash rate with customers at month-end. However, throughout the month, the Cloud Hash Rate may transition to Self-mining hash rate if customers opt to not make their monthly electricity payments for various reasons.
• Hosting encompasses a one-stop mining machine hosting solution including deployment, maintenance, and management services for efficient cryptocurrency mining.

²
Self-owned mining machines are for the Company’s self-mining business and Cloud Hash Rate business.
³Bitcoins held do not include the Bitcoins from deposits of the customers.

Infrastructure Construction Update

Rockdale, Texas

– 100 MW Hydro-cooling conversion to be energized in phases in Q1 2025:

• Cooling system will be delivered and installed in phases in Q1 2025.
• Planning for phased energization between January and March 2025.

Tydal, Norway
– 175 MW site expansion anticipated to be fully energized by mid-2025:

• Installation of the transformers has been completed, with the delivery and installation of electrical equipment currently in progress. Additionally, the procurement and delivery of containers and hydro-cooling systems are underway, and drainage systems construction is ongoing.
• Tydal, Norway Phase 1 40 MW expansion pending regulatory approval. Energization of the full 175 MW site is reasonably expected to be no later than mid-2025.

Massillon, Ohio

– 221 MW site construction has begun ahead of schedule:

• Substation construction is underway and is expected to be completed in Q3 2025.
• Building design is completed and construction has begun earlier than expected, estimated to be completed in phases between Q3 and Q4 2025.
• Estimated energization timeline remains on track for mid-to-late 2025.

Jigmeling, Bhutan

– 500 MW site is progressing well, with the following key milestones achieved:

• Construction of transformer and container foundations in progress and will be completed in phases, with the last phase expected by the end of February 2025.
• 132kb/140MW and 220kv/360MW substation designs are completed with construction anticipated to be ready by the end of Q1 2025.
• Orders for the procurement of transformers and electrical equipment have been placed, with delivery and installation work to be completed in phases over Q1 and Q2 2025.
• Procurement and delivery of containers and hydro-cooling systems are in progress, with completion in phases by the end of Q1 2025.

Site / Location	Capacity (MW)	Status	Timing4
Electrical capacity
– Rockdale, Texas	563	Online	Completed
– Knoxville, Tennessee	86	Online	Completed
– Wenatchee, Washington	13	Online	Completed
– Molde, Norway	84	Online	Completed
– Tydal, Norway	50	Online	Completed
– Gedu, Bhutan	100	Online	Completed
Total electrical capacity	8955
Pipeline capacity
– Tydal, Norway Phase 1	40	In progress	Pending Regulatory Approval
– Tydal, Norway Phase 2	135	In progress	Mid 2025
– Massillon, Ohio	221	In progress	Mid-to-late 2025
– Clarington, Ohio Phase 1	266	In progress	Q3 2025
– Clarington, Ohio Phase 2	304	Pending approval	Estimate 2026
– Jigmeling, Bhutan	500	In progress	Mid-to-late 2025
– Rockdale, Texas	179	In planning	Estimate 2026
Total pipeline capacity	1,645
Total global electrical capacity	2,540

⁴ Indicative timing. All timing references are to calendar quarters and years.
⁵ Figures may not add up due to rounding.

Upcoming Conferences and Events

• January 14-17, 2025: 27^th Annual Needham Growth Conference in New York City
  • Management Presentation is scheduled for 9:30 am ET on January 15, 2025 and can be viewed at this link.

About Bitdeer Technologies Group

Bitdeer is a world-leading technology company for blockchain and high-performance computing. Bitdeer is committed to providing comprehensive computing solutions for its customers. The Company handles complex processes involved in computing such as equipment procurement, transport logistics, datacenter design and construction, equipment management, and daily operations. The Company also offers advanced cloud capabilities to customers with high demand for artificial intelligence. Headquartered in Singapore, Bitdeer has deployed datacenters in the United States, Norway, and Bhutan. To learn more, visit https://ir.bitdeer.com/ or follow Bitdeer on X @ BitdeerOfficial and LinkedIn @ Bitdeer Group.

Investors and others should note that Bitdeer may announce material information using its website and/or on its accounts on social media platforms, including X, formerly known as Twitter, Facebook, and LinkedIn. Therefore, Bitdeer encourages investors and others to review the information it posts on the social media and other communication channels listed on its website.

Forward-Looking Statements

Statements in this press release about future expectations, plans, and prospects, as well as any other statements regarding matters that are not historical facts, may constitute “forward-looking statements” within the meaning of The Private Securities Litigation Reform Act of 1995. The words “anticipate,” “look forward to,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including factors discussed in the section entitled “Risk Factors” in Bitdeer’s annual report on Form 20-F, as well as discussions of potential risks, uncertainties, and other important factors in Bitdeer’s subsequent filings with the U.S. Securities and Exchange Commission. Any forward-looking statements contained in this press release speak only as of the date hereof. Bitdeer specifically disclaims any obligation to update any forward-looking statement, whether due to new information, future events, or otherwise. Readers should not rely upon the information on this page as current or accurate after its publication date.

For investor and media inquiries, please contact:

Investor Relations
Orange Group
Yujia Zhai
[email protected]

Public Relations
BlocksBridge Consulting
Nishant Sharma
[email protected]

SOUTH SAN FRANCISCO, Calif., Jan. 08, 2025 (GLOBE NEWSWIRE) — CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced that Sean McCarthy, D.Phil., chief executive officer and chairman, will present at the 43^rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025, at 1:30 p.m. PT.

A live webcast of the presentation will be available on the Events and Presentations page of CytomX’s website at www.cytomx.com. In addition, management will be available for one-on-one meetings with investors who are registered to attend the conferences.

About CytomX Therapeutics

CytomX is a clinical-stage, oncology-focused biopharmaceutical company focused on developing novel conditionally activated, masked biologics designed to be localized to the tumor microenvironment. By pioneering a novel pipeline of localized biologics, powered by its PROBODY® therapeutic platform, CytomX’s vision is to create safer, more effective therapies for the treatment of cancer. CytomX’s robust and differentiated pipeline comprises therapeutic candidates across multiple treatment modalities including antibody-drug conjugates (“ADCs”), T-cell engagers, and immune modulators such as cytokines. CytomX’s clinical-stage pipeline includes CX-904, CX-2051 and CX-801. CX-904 is a masked, conditionally activated T-cell-engaging bispecific antibody targeting the epidermal growth factor receptor (EGFR) on tumor cells and the CD3 receptor on T cells. CX-904 is partnered with Amgen in a global co-development alliance. CX-2051 is a masked, conditionally activated ADC directed toward epithelial cell adhesion molecule (EpCAM) and armed with a topoisomerase-1 inhibitor payload. CX-2051 has potential applicability across multiple EpCAM-expressing epithelial cancers and was discovered in collaboration with ImmunoGen, now part of AbbVie. CX-801 is a masked interferon alpha-2b PROBODY® cytokine with broad potential applicability in traditionally immuno-oncology sensitive as well as insensitive (cold) tumors. CytomX has established strategic collaborations with multiple leaders in oncology, including Amgen, Astellas, Bristol Myers Squibb, Regeneron and Moderna. For more information about CytomX and how it is working to make conditionally activated treatments the new standard-of-care in the fight against cancer, visit www.cytomx.com and follow us on LinkedIn and X (formerly Twitter).

Company Contact:

Chris Ogden
SVP, Chief Financial Officer
[email protected]

Investor Contact:

Precision AQ (formerly Stern Investor Relations)
Stephanie Ascher
[email protected]

Media Contact:

Redhouse Communications
Teri Dahlman
[email protected]

AURORA, Ontario, Jan. 08, 2025 (GLOBE NEWSWIRE) — Magna International Inc. (TSX:MG) (NYSE:MGA)

MAGNA INTERNATIONAL INC. ANNOUNCES DATE FOR  Q4 & YEAR END 2024 RESULTS and 2025 OUTLOOK WEBCAST
FRIDAY, FEBRUARY 14, 2025 @ 8:00 AM ET
LIVE AUDIO WEBCAST Webcast registration: https://events.q4inc.com/attendee/672335329
DIAL-IN DETAILS
Participant Toll-Free Dial-In:	1-800-715-9871
Participant Toll Dial-In:	1-646-307-1963
Conference ID:	9829976
Slide presentation will be available on our website Investors | Magna prior to the call
REBROADCAST INFORMATION
Replay available 2 hours after the call until February 21, 2025
Toll-Free Dial-In:	1-800-770-2030
Toll Dial-In:	1-609-800-9909
Conference ID:	9829976

INVESTOR CONTACT

Louis Tonelli, Vice-President, Investor Relations
[email protected] 905-726-7035

WEBCAST CONTACT

Nancy Hansford, Executive Assistant, Investor Relations
[email protected] 905-726-7108

ABOUT MAGNA INTERNATIONAL

Magna is more than one of the world’s largest suppliers in the automotive space. We are a mobility technology company built to innovate, with a global, entrepreneurial-minded team of over 175,000 employees across 343 manufacturing operations and 107 product development, engineering and sales centres spanning 28 countries. With 65+ years of expertise, our ecosystem of interconnected products combined with our complete vehicle expertise uniquely positions us to advance mobility in an expanded transportation landscape.

For further information about Magna (NYSE:MGA; TSX:MG), please visit www.magna.com or follow us on social.

NEW YORK, Jan. 08, 2025 (GLOBE NEWSWIRE) — Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus” or the “Company”), a clinical-stage biotechnology company pioneering innovative cancer and viral infection treatments, today highlights its accomplishments in 2024 and outlines the Company’s strategic goals for the year ahead.

Advancing Decoy20 in Clinical Trials

2024 was a year of meaningful progress for Indaptus’ lead clinical candidate, Decoy20, a novel immunotherapy designed to harness both innate and adaptive immune responses. Highlights from the Company’s Phase 1 clinical trial include:

• Second Cohort Results (March 2024): Building on the Company’s November 2023 findings, Decoy20 demonstrated a broad immune response across multiple tumor types in patients, underscoring the platform’s potential as a monotherapy.
• Weekly-Dose Cohort Initiation (May 2024): After receiving Safety Review Committee approval, the Company dosed its first patient in the weekly-dose portion of the trial. Notably, no new, clinically significant treatment-related adverse effects were observed.
• Higher Dose Expansion (September 2024): Following a positive safety review, Indaptus initiated a higher-dose weekly regimen, further expanding the scope of the trial to evaluate Decoy20’s safety and efficacy.

Key Scientific
Presentations, Publications and Advancements

Indaptus showcased Decoy20’s potential through a variety of presentations at major industry conferences and peer reviewed journals:

• AACR Annual Meeting (April 2024): Demonstrated that Decoy activates multiple innate and adaptive immune cell types, highlighting its promise as an anti-tumor therapeutic.
• ASCO Annual Meeting (June 2024): Shared promising preliminary results, including immune marker activation in patients with advanced solid tumors following a single dose of Decoy20.
• STING & TLR Targeted Therapies Summit (June 2024): Dr. Michael Newman was named meeting Chairperson for the second year in a row, and presented pre-clinical and clinical Decoy data.
• Frontiers in Immunology (November 2024): Dr. Michael Newman’s groundbreaking research on the Decoy platform was published in Frontiers in Immunology, further validating the Company’s scientific foundation and enhancing visibility within the scientific community.
• Society for Immunotherapy of Cancer (SITC) (November 2024): Presented encouraging data highlighting consistent safety outcomes with weekly Decoy20 dosing, while demonstrating its sustained ability to activate the immune system over time.
• Decoy platform: The Company made significant progress expanding its Decoy platform, successfully producing engineered Decoy bacteria designed to activate targeted immune pathways, enhancing its potential for broader therapeutic applications.

Clinical Supply Agreement with BeiGene

In October 2024, Indaptus achieved a key milestone when it announced a clinical supply agreement with BeiGene to advance the evaluation of Decoy20 in combination with their PD-1 checkpoint inhibitor, tislelizumab. This agreement underscores the potential versatility of the Decoy platform as a standalone therapy and in synergy with an approved immunotherapy treatment modality. This clinical combination is important because, in pre-clinical animal models, Decoy20 demonstrated significant anti-tumor synergy in combination with a PD-1 checkpoint inhibitor.

Financial Strength

Indaptus raised a total of $5.5 million in 2024 through a series of strategic financing initiatives, ensuring funding to support ongoing research and development efforts into 2025.

2025 Outlook

Jeffrey Meckler, CEO of Indaptus Therapeutics, commented, “As we enter 2025, we remain committed to advancing Decoy20 through clinical trials and exploring its combination potential with BeiGene’s tislelizumab. We are excited about the progress we made in 2024 and optimistic about the transformative potential of our platform to address some of the most challenging cancers.”

Indaptus intends to maintain its commitment to robust data generation, with plans to share new findings at leading scientific forums as they become available, while actively pursuing opportunities to expand the applications of its Decoy platform.

The Company currently anticipates that it will achieve the following milestones in the first half of 2025:

• Launch of Combination Cohort: The Company plans to open an amendment to its clinical trial to include a combination cohort evaluating Decoy20 in conjunction with the PD-1 checkpoint inhibitor, tislelizumab.
• Expansion of Clinical Sites: Building on its progress in 2024, the Company intends to increase the number of participating clinical sites beyond the eight active locations at the end of last year, enabling broader patient enrollment.
• Higher Dose Cohort Update: The Company plans to provide an update on the patients treated in the higher dose expansion cohort, providing insights into safety and immune activation at this dose level.
• First Patient Dosed in Combination Cohort: The Company aims to start dosing the first patients in the combination cohort, marking an important step in evaluating Decoy20’s synergistic potential with checkpoint inhibitors.

The company believes these milestones, if achieved, will represent significant advancements in the clinical development of Decoy20 and the broader Decoy platform.

About Indaptus Therapeutics

Indaptus Therapeutics has evolved from more than a century of immunotherapy advances. The Company’s novel approach is based on the hypothesis that efficient activation of both innate and adaptive immune cells and pathways and associated anti-tumor and anti-viral immune responses will require a multi-targeted package of immune system-activating signals that can be administered safely intravenously (i.v.). Indaptus’ patented technology is composed of single strains of attenuated and killed, non-pathogenic, Gram-negative bacteria producing a multiple Toll-like receptor (TLR), Nucleotide oligomerization domain (NOD)-like receptor (NLR) and Stimulator of interferon genes (STING) agonist Decoy platform. The product candidates are designed to have reduced i.v. toxicity, but largely uncompromised ability to prime or activate many of the cells and pathways of innate and adaptive immunity. Decoy product candidates represent an antigen-agnostic technology that have produced single-agent activity against metastatic pancreatic and orthotopic colorectal carcinomas, single agent eradication of established antigen-expressing breast carcinoma, as well as combination-mediated eradication of established hepatocellular carcinomas, pancreatic and non-Hodgkin’s lymphomas in standard pre-clinical models, including syngeneic mouse tumors and human tumor xenografts. In pre-clinical studies tumor eradication was observed with Decoy product candidates in combination with anti-PD-1 checkpoint therapy, low-dose chemotherapy, a non-steroidal anti-inflammatory drug, or an approved, targeted antibody. Combination-based tumor eradication in pre-clinical models produced innate and adaptive immunological memory, involved activation of both innate and adaptive immune cells, and was associated with induction of innate and adaptive immune pathways in tumors after only one i.v. dose of Decoy product candidate, with associated “cold” to “hot” tumor inflammation signature transition. IND-enabling, nonclinical toxicology studies demonstrated i.v. administration without sustained induction of hallmark biomarkers of cytokine release syndromes, possibly due to passive targeting to liver, spleen, and tumor, followed by rapid elimination of the product candidate. Indaptus’ Decoy product candidates have also produced meaningful single agent activity against chronic hepatitis B virus (HBV) and chronic human immunodeficiency virus (HIV) infections in pre-clinical models.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act. These include statements regarding management’s expectations, beliefs and intentions regarding, among other things: our expectations and plans regarding our clinical supply agreement with BeiGene; our plans to advance clinical evaluation of the combination of BeiGene’s anti-PD-1 antibody, tislelizumab, with Decoy20; our plans to seek FDA approval and to initiate a combination trial; the plans and objectives of management for future operations; our research and development activities; and the sufficiency of our cash and cash equivalents to fund our ongoing activities. Forward-looking statements can be identified by the use of forward-looking words such as “believe”, “expect”, “intend”, “plan”, “may”, “should”, “could”, “might”, “seek”, “target”, “will”, “project”, “forecast”, “continue” or “anticipate” or their negatives or variations of these words or other comparable words or by the fact that these statements do not relate strictly to historical matters. Because forward-looking statements relate to matters that have not yet occurred, these statements are inherently subject to risks and uncertainties that could cause our actual results to differ materially from any future results expressed or implied by the forward-looking statements. Many factors could cause actual activities or results to differ materially from the activities and results anticipated in forward-looking statements, including, but not limited to the following: our limited operating history; conditions and events that raise substantial doubt regarding our ability to continue as going concern; the need for, and our ability to raise, additional capital given our lack of current cash flow; our clinical and preclinical development, which involves a lengthy and expensive process with an uncertain outcome; our incurrence of significant research and development expenses and other operating expenses, which may make it difficult for us to attain profitability; our pursuit of a limited number of research programs, product candidates and specific indications and failure to capitalize on product candidates or indications that may be more profitable or have a greater likelihood of success; our ability to obtain and maintain regulatory approval of any product candidate; the market acceptance of our product candidates; our reliance on third parties to conduct our preclinical studies and clinical trials and perform other tasks; our reliance on third parties for the manufacture of our product candidates during clinical development; our ability to successfully commercialize Decoy20 or any future product candidates; our ability to obtain or maintain coverage and adequate reimbursement for our products; the impact of legislation and healthcare reform measures on our ability to obtain marketing approval for and commercialize Decoy20 and any future product candidates; product candidates of our competitors that may be approved faster, marketed more effectively, and better tolerated than our product candidates; our ability to adequately protect our proprietary or licensed technology in the marketplace; the impact of, and costs of complying with healthcare laws and regulations, and our failure to comply with such laws and regulations; information technology system failures, cyberattacks or deficiencies in our cybersecurity; and unfavorable global economic conditions. These and other important factors discussed under the caption “Risk Factors” included in our Quarterly Report on Form 10-Q for the quarter ended September 30, 2024 filed with the SEC on November 12, 2024, our most recent Annual Report on Form 10-K filed with the SEC on March 13, 2024, and our other filings with the SEC, could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. All forward-looking statements speak only as of the date of this press release and are expressly qualified in their entirety by the cautionary statements included in this press release. We undertake no obligation to update or revise forward-looking statements to reflect events or circumstances that arise after the date made or to reflect the occurrence of unanticipated events, except as required by applicable law.

Contact: [email protected]

Investor Relations Contact:

CORE IR
Louie Toma
[email protected]

NEW YORK, Jan. 08, 2025 (GLOBE NEWSWIRE) — Bonaccord Capital Partners (“Bonaccord”), a private equity business focused on providing growth capital and strategic support to middle-market private markets sponsors, today announced the final close of its second GP Stakes fund, Bonaccord Capital Partners II (“BCP II” or the “Fund”), with $1.6 billion in total commitments. The Fund closed at its revised hard cap and above its target of $1.25B, having grown by 117% compared to its predecessor fund Bonaccord Capital Partners I (“BCP I”), a 2021 vintage that closed with $738.95 million. Amidst growth in fund size, Bonaccord has maintained a consistent focus on investing in exceptional mid-market private markets sponsors. With the close of BCP II, Bonaccord now has approximately $5.0 billion in assets under management.

BCP II received significant support from existing investors, with BCP I LPs having increased their aggregate commitment by 17% vs. prior fund commitments. The Fund has a diverse LP base, including 66 investors across 4 continents and 14 countries, and experienced meaningful growth in investor count across important geographies including the Middle East, Asia, and Latin America. BCP II also substantially increased investor count across growth segments including wealth and insurance.

“The closing of Bonaccord Capital Partners II is a testament to the exceptional caliber of our partner sponsors, and we are grateful to share a vision of long-term growth and partnership with all of them,” said Ajay Chitkara, Managing Partner at Bonaccord. “We thank our investors for the confidence they have placed in us to execute our investment strategy, and we will continually endeavor to achieve ongoing success for all Bonaccord stakeholders.”

To-date, Bonaccord has invested $2.6B across 15 investments, including $1.0B of co-investment. BCP II will continue Bonaccord’s middle-market GP stakes strategy, partnering with exceptional middle-market private markets sponsors across private equity, private credit, real estate and real assets with the mission of supporting them to reach their potential and establish enduring institutions. BCP II is approximately 60% invested to-date and has completed 8 investments in Park Square Capital, Trivest Partners, Shamrock Capital, VMG Partners, Synova Capital, Revelstoke Capital Partners, Kayne Anderson Private Credit, and Lead Edge Capital. Bonaccord is continuing to invest in team and corporate resources to support this larger fund and anticipated future initiatives.

Fried, Frank, Harris, Shriver & Jacobson LLP served as fund counsel.

About Bonaccord Capital Partners

Bonaccord Capital Partners (“Bonaccord”) is a private equity business focused on providing growth capital and strategic support to exceptional mid-market private markets sponsors spanning private equity, private credit, and real estate and real assets. By leveraging its strategic relationships, institutional capabilities, and strategic development expertise, Bonaccord seeks to support transformative initiatives and portfolio objectives that help its partner sponsors reach their potential and establish enduring institutions. Bonaccord is a part of P10, Inc. (NYSE: PX), a leading multi-asset class private markets solutions provider in the alternative asset management industry. For more information, please visit www.bonaccordcapital.com.

Contact:

Investor Relations:
Sophia Kolodzinski
[email protected]
[email protected]

Media Relations:
Prosek Partners
[email protected]